How to Get Enclomiphene Citrate in Connecticut

What Is Enclomiphene Citrate and Why Is It Prescribed?

Enclomiphene citrate is the trans-isomer of clomiphene citrate, an estrogen-receptor antagonist that blocks hypothalamic feedback inhibition and raises gonadotropin-releasing hormone (GnRH) pulse frequency. This causes the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives endogenous testosterone production without suppressing spermatogenesis. Physicians prescribe it off-label for secondary hypogonadism in men who want to maintain fertility or avoid the testicular atrophy associated with exogenous testosterone therapy [1].

The most cited controlled trial is Kim et al. (BJU Int, 2016, N=124), which showed that enclomiphene citrate 12.5 mg or 25 mg daily raised mean serum testosterone from 230 ng/dL to above 400 ng/dL within 12 weeks while preserving normal sperm parameters [1]. A separate Phase III study by Wiehle et al. found that 25 mg daily normalized testosterone in 74.6% of men with secondary hypogonadism at eight weeks, compared with 3.4% in the placebo arm [2]. The Endocrine Society's clinical practice guideline on male hypogonadism notes that clomiphene-class agents may be considered for men with secondary hypogonadism who wish to preserve fertility, though the guideline cautions that long-term randomized data remain limited [3].

Enclomiphene is not the same as clomiphene citrate (Clomid), which also contains the cis-isomer zuclomiphene. The cis-isomer accumulates in tissue over time and may contribute to side effects including visual disturbances and mood changes. By isolating only the trans-isomer, compounded enclomiphene aims to reduce that accumulation [4].

Is Enclomiphene Citrate Legal to Prescribe in Connecticut?

Prescribing enclomiphene citrate in Connecticut is legal for licensed practitioners treating secondary hypogonadism, even though it remains off-label under FDA regulations. Connecticut's telehealth statute (Conn. Gen. Stat. § 19a-906) permits synchronous and asynchronous prescribing by any Connecticut-licensed prescriber without a mandatory prior in-person visit for most conditions [5]. This means a Connecticut-licensed physician, NP, or PA can evaluate, diagnose, and prescribe enclomiphene after a telehealth encounter, provided the encounter meets the standard of care for a complete history and physical assessment.

The FDA has not approved a standalone enclomiphene citrate product for commercial sale in the United States as of the article's last review date. The agency previously issued a Complete Response Letter to Repros Therapeutics regarding Androxal (enclomiphene citrate 25 mg) in 2014, requesting additional safety data. Because no FDA-approved finished product is currently available, prescribers and patients rely on 503A compounding pharmacies to prepare the medication [6]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound enclomiphene for an individual patient upon receipt of a valid prescription from a licensed practitioner [7].

Connecticut's Department of Consumer Protection Board of Pharmacy licenses compounding pharmacies operating within state borders. Patients may also receive shipments from out-of-state 503A pharmacies licensed in their home state, provided that pharmacy also holds a Connecticut non-resident pharmacy permit [8].

Who Can Prescribe Enclomiphene Citrate in Connecticut?

Any Connecticut-licensed prescriber with authority to prescribe non-controlled medications may write an enclomiphene prescription. That includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO): Full prescribing authority under Connecticut General Statutes § 20-9.
• Advanced practice registered nurses (APRN): Prescriptive authority through a Connecticut Controlled Substance Registration; enclomiphene is not a controlled substance, so APRNs with collaborative agreements may prescribe it freely.
• Physician assistants (PA): Prescriptive authority under Connecticut § 20-12d, typically subject to a supervising physician relationship for off-label compounds.

Telehealth providers operating under a Connecticut license carry the same prescribing authority as in-person providers for this drug class. Patients should confirm that any online platform they use employs a prescriber holding an active Connecticut license, not just a license in the platform's home state [5].

What Labs Are Required Before Starting Enclomiphene in Connecticut?

Baseline laboratory work is not optional. Connecticut's standard of care for prescribing enclomiphene aligns with the Endocrine Society guideline recommendation that a confirmed low testosterone (two fasting morning measurements below 300 ng/dL) plus clinical symptoms must precede treatment [3]. The Endocrine Society guideline states: "We recommend measurement of morning total testosterone levels on at least two separate occasions before establishing the diagnosis of androgen deficiency." [3]

Required labs at most Connecticut telehealth and in-person clinics include:

• Total testosterone (morning draw, two separate occasions for diagnosis confirmation)
• LH and FSH (to confirm secondary, not primary, hypogonadism)
• Estradiol (E2) (baseline for monitoring during treatment)
• Sex hormone-binding globulin (SHBG) (to calculate free testosterone when total is borderline)
• Complete blood count (CBC) (hematocrit screening, given testosterone's erythropoietic effects)
• Comprehensive metabolic panel (CMP) (liver function, given hepatic metabolism of clomiphene-class agents)
• Prolactin (to exclude prolactinoma as a cause of secondary hypogonadism)
• TSH (thyroid dysfunction mimics hypogonadal symptoms)

Quest Diagnostics and LabCorp both operate draw sites throughout Connecticut, including locations in Bridgeport, Hartford, New Haven, Stamford, and Waterbury. Most telehealth platforms send electronic lab requisitions directly, so patients can complete draws within 24 hours of their online consult [9].

Follow-up labs are typically drawn at 6 to 8 weeks after starting treatment to confirm testosterone response and check estradiol, since enclomiphene's estrogen-receptor antagonism at the hypothalamus may secondarily raise estradiol through increased aromatase substrate [1].

How to Get an Enclomiphene Citrate Prescription in Connecticut Step by Step

The process follows a predictable sequence at most Connecticut-accessible practices:

Step 1: Select a licensed Connecticut provider. Choose a telehealth platform or local urologist, endocrinologist, or men's health clinic whose prescribers hold active Connecticut licenses. Verify licensure through the Connecticut Department of Public Health License Lookup portal.

Step 2: Complete an intake questionnaire. Most platforms collect a detailed symptom history including fatigue, libido, erectile function, mood, and prior testosterone or fertility treatments. Providing complete medication and allergy history here prevents prescribing delays.

Step 3: Order and complete baseline labs. The provider sends a requisition. Most Connecticut residents use a LabCorp or Quest site. Fasting morning draws for testosterone should be completed between 7 a.m. and 10 a.m. to capture the diurnal peak [3].

Step 4: Attend a synchronous or asynchronous telehealth visit. The prescriber reviews labs, confirms secondary hypogonadism, discusses risks and benefits, and either prescribes or requests additional workup.

Step 5: Pharmacy fulfillment. The prescription routes to a 503A compounding pharmacy licensed in Connecticut or holding a Connecticut non-resident permit. Oral capsules or tablets at 12.5 mg or 25 mg are the standard dose forms [6].

Step 6: Receive shipment. Standard shipping from a licensed 503A pharmacy runs three to five business days for most Connecticut ZIP codes. Overnight shipping adds one to two business days for rural areas.

Connecticut Medicaid Coverage and Prior Authorization

Connecticut Medicaid (HUSKY Health) covers compounded enclomiphene citrate for secondary hypogonadism with prior authorization. The prior authorization process requires documentation of:

1. Two separate serum total testosterone measurements below 300 ng/dL.
2. Symptomatic androgen deficiency per the Androgen Deficiency in Aging Males (ADAM) questionnaire or equivalent.
3. LH and FSH results confirming the secondary (hypogonadotropic) etiology.
4. A 30-day trial of lifestyle modification (weight loss, sleep optimization, alcohol reduction) documented in the chart when the patient has BMI <35 and no urgent symptoms.
5. Prescriber attestation that exogenous testosterone is contraindicated or declined due to fertility preservation intent.

Connecticut Medicaid's preferred drug list does not include an FDA-approved enclomiphene product, so the PA is submitted as a non-preferred, off-label compounded medication under the pharmacy benefit. Approval timelines for PA decisions in Connecticut average 14 business days for standard reviews and 72 hours for expedited clinical reviews [10]. Most commercial insurers in Connecticut, including Aetna (headquartered in Hartford) and ConnectiCare, apply similar documentation requirements, though coverage determinations vary by individual plan.

Dosing, Titration, and Monitoring in Connecticut Practice

Connecticut prescribers generally follow the dosing protocol established in the Kim et al. and Wiehle et al. trials. Standard starting doses are 12.5 mg once daily for patients with baseline testosterone between 200 and 300 ng/dL and 25 mg once daily for those below 200 ng/dL [1][2]. Both doses are taken orally each morning.

At the 6 to 8 week follow-up:

• If total testosterone reaches 400 to 700 ng/dL, the dose is maintained.
• If testosterone remains below 350 ng/dL, the prescriber may titrate to 25 mg (from 12.5 mg) or 50 mg (from 25 mg) as clinically indicated.
• Estradiol above 40 pg/mL at follow-up may prompt the addition of a low-dose aromatase inhibitor, though this is an additional off-label step requiring prescriber judgment [3].

The American Urological Association (AUA) guidelines on testosterone deficiency state that any testosterone therapy requires monitoring of hematocrit, PSA (in men over 40), and symptom response at three and twelve months [11]. Connecticut prescribers align enclomiphene monitoring with those intervals.

Visual symptoms, including blurred vision or scotomata, occur in roughly 1.5% to 2% of men on clomiphene-class agents and warrant prompt ophthalmologic evaluation and drug discontinuation [4]. Mood changes, hot flashes, and nausea are the other most frequently reported adverse effects.

503A Compounding Pharmacies That Serve Connecticut Patients

No FDA-approved commercial enclomiphene product exists, so all Connecticut dispensing runs through 503A compounding pharmacies. Under 503A, a pharmacy compounds for a specific patient under a specific prescription, and the compound is not sold in bulk [7].

Patients should confirm their pharmacy holds:

• A Connecticut pharmacy license or a Connecticut non-resident pharmacy permit issued by the Department of Consumer Protection.
• USP 795 or USP 800 compliance certification (oral non-sterile compounding standard).
• A National Association of Boards of Pharmacy (NABP) e-Profile or PCAB accreditation, which signals third-party quality review [8].

Enclomiphene is supplied as oral capsules or tablets, typically in 12.5 mg, 25 mg, or 50 mg strengths. Compound cost without insurance averages $80 to $150 per 30-day supply across Connecticut-accessible pharmacies, depending on dose and pharmacy. Patients using Connecticut Medicaid with an approved PA may pay $0 to $3 depending on the HUSKY Health tier [10].

Transferring an Existing Enclomiphene Prescription to Connecticut

Patients relocating to Connecticut from another state often ask whether they can transfer an existing enclomiphene prescription. The answer depends on how the original prescription was written:

• Electronic prescriptions written to a specific pharmacy: These can be transferred to a Connecticut-licensed pharmacy only if the original pharmacy has not yet dispensed any fills. Under federal law (21 CFR Part 1306), Schedule II controlled substances cannot be transferred, but enclomiphene is unscheduled, so transfer is permitted under standard pharmacy law.
• Paper or phone prescriptions: Connecticut pharmacies accept these from out-of-state licensed prescribers only if those prescribers are licensed in Connecticut. Most telehealth platforms employ prescribers licensed in all 50 states, which makes transfer straightforward.
• Prescription written by an out-of-state prescriber not licensed in Connecticut: Connecticut pharmacies cannot legally fill this. The patient must establish care with a Connecticut-licensed provider. Telehealth platforms make this process the same day in most cases.

Providing the receiving pharmacy with the original prescription number, pharmacy name, and phone number accelerates the transfer. Most Connecticut pharmacies complete transfers within four business hours [8].

Why Enclomiphene Rather Than Testosterone Replacement Therapy?

Connecticut prescribers and patients increasingly ask this comparison question. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and causing spermatogenesis to decline or cease, often within 90 days of starting therapy [11]. For men who want biological children, that is a direct contraindication.

A 2020 meta-analysis published in the Journal of Urology (Patel et al., N=657 across 7 studies) found that clomiphene citrate and enclomiphene citrate maintained mean sperm concentration above 15 million/mL in 88% of men with secondary hypogonadism, while total testosterone rose to above 400 ng/dL in 71% of participants [12]. Exogenous testosterone achieved testosterone normalization in nearly 100% of men, but caused azoospermia or severe oligospermia in approximately 65% of those same men during treatment [11].

The trade-off is efficacy ceilings. Enclomiphene works only when the pituitary and testes are functional. Men with primary hypogonadism (high LH, low testosterone), Klinefelter syndrome, or prior chemotherapy-related testicular damage will not respond to enclomiphene because the target of the drug (hypothalamic feedback) is not the source of their hormone deficit [3].

Common Reasons Connecticut Enclomiphene Prescriptions Are Delayed

Delays cluster around four areas:

1. Incomplete labs. Missing LH and FSH values prevent the prescriber from confirming the secondary etiology. This is the single most common source of delay reported by Connecticut telehealth platforms.
2. Single testosterone draw. Endocrine Society guidelines require two separate morning measurements. A provider who proceeds on one draw is not meeting the documented standard of care, and a cautious prescriber will order a repeat [3].
3. Pharmacy permitting gaps. If a patient's preferred pharmacy lacks a Connecticut non-resident permit, the prescription must be re-routed before dispensing can occur. Confirming pharmacy licensure upfront eliminates this.
4. Prior authorization backlog. Connecticut Medicaid PA queues average 14 business days. Patients with commercial insurance on plans requiring PA can face similar timelines. Starting with a cash-pay option while the PA processes is a practical bridge many Connecticut prescribers offer [10].

Frequently Asked Questions